Company profile: Shorla Oncology
1.1 - Company Overview
Company description
- Provider of innovative oncology drugs focused on women's and pediatric cancers, developing and commercializing life-saving treatments that address unmet needs. Portfolio includes FDA-approved JYLAMVO (oral methotrexate) and TEPYLUTE for breast and ovarian cancer, as well as a Nelarabine Injection; pipeline programs include SH-201 under FDA review and SH-110 in development.
Products and services
- TEPYLUTE (SH-105): FDA-approved treatment offering a new option for women with breast and ovarian cancer, addressing these two indications explicitly
- JYLAMVO: FDA-approved oral methotrexate solution treating acute lymphoblastic leukemia, mycosis fungoides, non-Hodgkin lymphoma, rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis across indicated patient populations
- Nelarabine Injection: Generic formulation indicated for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in patients unresponsive to or relapsed after at least two chemotherapy regimens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Shorla Oncology
NeoGenomics
HQ: United States
Website
- Description: Provider of cancer testing and partnership programs for pathologists and oncologists, offering diagnostic services (flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers), anatomic pathology (histology, tissue staining, digital pathology), NGS panels including Neo Comprehensive™ – Heme Cancers, Early-stage NSCLC Panel, InVisionFirst®-Lung, and pharma services for biomarker discovery, clinical trials, and companion diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoGenomics company profile →
Synta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule therapeutics to treat cancer and chronic inflammatory diseases, focused on the development and commercialization of these drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synta Pharmaceuticals company profile →
Seagen
HQ: United States
Website
- Description: Provider of monoclonal antibody-based therapies and advanced antibody-drug conjugate technology focused on improving patient outcomes in cancer and autoimmune diseases. Lead program SGN-35 is in a pivotal trial for patients with relapsed or refractory Hodgkin lymphoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seagen company profile →
Transgene
HQ: France
Website
- Description: Provider of integrated immunotherapies to treat cancers and chronic infectious diseases, covering research, clinical batch manufacturing, and clinical trials. Portfolio includes TG4050 personalized neoantigen cancer vaccine using genetic engineering and AI; TG4001 therapeutic HPV-16 cancer vaccine; BT-001 (anti-CTLA4, GM-CSF) and TG6050 (IL-12, anti-CTLA4) oncolytic viruses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transgene company profile →
Progenics Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Progenics Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Shorla Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Shorla Oncology
2.2 - Growth funds investing in similar companies to Shorla Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Shorla Oncology
4.2 - Public trading comparable groups for Shorla Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →